On July 9, 2024,   ZHB110 sublingual tablet, a Class 1 new drug of therapeutic biological products, which was originally developed by ZONHONBIO, with full independent intellectual property rights both at home and abroad, received the Clinical Trial Approval Notice from the NMPA. The approved indication is Artemisia-induced allergic rhinitis with or without conjunctivitis.